Sugi Predict

Sugi Predict / Compounds / SCHEMBL1786788

SCHEMBL1786788

SCHEMBL1786788

Nc1ncnc2c1c(I)cn2C1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 3/20 0.58
▸ SRC P12931 5/20 0.56
▸ LCK P06239 3/20 0.56
▸ TEK Q02763 2/20 0.56
▸ HCK P08631 1/20 0.56
▸ ADK P55263 10/20 0.55
▸ MTOR P42345 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ABL1 P00519 3/20 0.50
▸ DAPK3 O43293 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50
▸ PAK4 O96013 1/20 0.50
▸ FYN P06241 1/20 0.50
▸ CSF1R P07333 1/20 0.50
▸ IGF1R P08069 1/20 0.50
▸ FGFR1 P11362 1/20 0.50
▸ PRKACA P17612 1/20 0.50
▸ FLT1 P17948 1/20 0.50
▸ LTK P29376 1/20 0.50
▸ KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237288 0.90 SRC (0.59) RETSRCLCKADKMTOR
SCHEMBL30155310 0.87 ABL1 (0.64) RETSRCLCKTEKADK
SCHEMBL400626 0.87 SRC (0.61) RETSRCLCKADKMTOR
SCHEMBL29484468 0.87 SRC (0.61) RETSRCLCKADKMTOR
SCHEMBL1940882 0.87 ABL1 (0.64) RETSRCLCKTEKADK
SCHEMBL23966749 0.86 ADK (0.61) RETSRCLCKTEKADK
SCHEMBL17818397 0.86 ABL1 (0.63) RETSRCLCKTEKADK
SCHEMBL1933267 0.84 RIPK2 (0.63) RETSRCLCKADKMTOR
SCHEMBL1933264 0.84 RIPK2 (0.63) RETSRCLCKADKMTOR
SCHEMBL1787110 0.83 ADK (0.52) RETSRCLCKTEKHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. 2025-05-15 — — US disclosed
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 — — US disclosed
EP-4247816-A1 SRC INHIBITORS AND USES THEREOF Relay Therapeutics, Inc. (US) 2023-09-27 — — EP disclosed
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 — — EP disclosed
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-04-06 — — US disclosed
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-11-08 — — US disclosed
WO-2022109551-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. (US) 2022-05-27 — — WO disclosed
WO-2022109551-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. (US) 2022-05-27 — — WO disclosed
CN-109311894-B N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors 内尔维阿诺医学科学有限公司 2022-03-22 — — CN disclosed
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-05-06 — — US disclosed
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use INTELLIKINE LLC 2015-08-13 — — US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 — — US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 — — US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 — — US disclosed
WO-2014184069-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-20 — — WO disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 — — US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 — — US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 — — US disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 — — WO disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 RET 959/4885SRC 161/4885LCK 396/4885
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 RET 959/4885SRC 161/4885LCK 396/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 RET 959/4885SRC 161/4885LCK 396/4885
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 RET 959/4885SRC 161/4885LCK 396/4885
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE MTOR, PDPK1, PIKFYVE RET 356/4885SRC 164/4885LCK 261/4885
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use MTOR, PDPK1, PIKFYVE RET 356/4885SRC 164/4885LCK 261/4885
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF SRC, LCK, FYN RET 56/4885SRC 1/4885LCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.